125 related articles for article (PubMed ID: 3862496)
1. Pefloxacin kinetics in cirrhosis.
Danan G; Montay G; Cunci R; Erlinger S
Clin Pharmacol Ther; 1985 Oct; 38(4):439-42. PubMed ID: 3862496
[TBL] [Abstract][Full Text] [Related]
2. Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis.
Cardey J; Silvain C; Bouquet S; Breux JP; Becq-Giraudon B; Fourtillan JP; Beauchant M
Eur J Clin Pharmacol; 1987; 33(5):469-72. PubMed ID: 3480805
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers.
Frydman AM; Le Roux Y; Lefebvre MA; Djebbar F; Fourtillan JB; Gaillot J
J Antimicrob Chemother; 1986 Apr; 17 Suppl B():65-79. PubMed ID: 3458699
[TBL] [Abstract][Full Text] [Related]
4. Transfer kinetics of pefloxacin into cerebro-spinal fluid after one hour i.v. infusion of 400 mg in man.
Dow J; Chazal J; Frydman AM; Janny P; Woehrle R; Djebbar F; Gaillot J
J Antimicrob Chemother; 1986 Apr; 17 Suppl B():81-7. PubMed ID: 3458700
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of pefloxacin in renal insufficiency.
Montay G; Jacquot C; Bariety J; Cunci R
Eur J Clin Pharmacol; 1985; 29(3):345-9. PubMed ID: 3865778
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetic behavior of pefloxacin in man].
Fourtillan JB
Rev Med Interne; 1986 Mar; 7(2):185-95. PubMed ID: 3459221
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of fluoroquinolones in hepatic failure.
Montay G; Gaillot J
J Antimicrob Chemother; 1990 Oct; 26 Suppl B():61-7. PubMed ID: 2258353
[TBL] [Abstract][Full Text] [Related]
8. Single-dose pefloxacin pharmacokinetics and metabolism in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Nikolaidis P; Walker SE; Dombros N; Tourkantonis A; Paton TW; Oreopoulos DG
Perit Dial Int; 1991; 11(1):59-63. PubMed ID: 2049424
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacokinetics of pefloxacin in burn patients].
Potel G; Meignier M; Touzé MD; Montay G; Drugeon HB; Baron D
Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):777-80. PubMed ID: 3309814
[TBL] [Abstract][Full Text] [Related]
10. Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment.
Jungers P; Ganeval D; Hannedouche T; Prieur B; Montay G
Eur J Clin Pharmacol; 1987; 33(5):463-7. PubMed ID: 3480804
[TBL] [Abstract][Full Text] [Related]
11. The comparative pharmacokinetics of five quinolones.
Wise R; Lister D; McNulty CA; Griggs D; Andrews JM
J Antimicrob Chemother; 1986 Nov; 18 Suppl D():71-81. PubMed ID: 3468102
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Bayesian estimation to discriminate subpopulations of patients with altered pharmacokinetics using fragmentary data: a pilot study with pefloxacin.
Bruno R; Rosier P; Iliadis A; Le Roux Y; Montay G; Frydman A; Gaillot J
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():338-45. PubMed ID: 1820906
[TBL] [Abstract][Full Text] [Related]
13. Pefloxacin concentrations in human aqueous humour and lens.
Salvanet A; Fisch A; Lafaix C; Montay G; Dubayle P; Forestier F; Haroche G
J Antimicrob Chemother; 1986 Aug; 18(2):199-201. PubMed ID: 3463558
[TBL] [Abstract][Full Text] [Related]
14. Ranitidine disposition in severe hepatic cirrhosis.
Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A
Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740
[TBL] [Abstract][Full Text] [Related]
15. Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.
Montay G; Goueffon Y; Roquet F
Antimicrob Agents Chemother; 1984 Apr; 25(4):463-72. PubMed ID: 6587830
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and protein binding of cefpiramide in patients with alcoholic cirrhosis.
Demotes-Mainard F; Vinçon G; Amouretti M; Dumas F; Necciari J; Kieffer G; Begaud B
Clin Pharmacol Ther; 1991 Mar; 49(3):263-9. PubMed ID: 2007321
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and tissue penetration of orally administered pefloxacin.
Webberley JM; Andrews JM; Ashby JP; McLeod A; Wise R
Eur J Clin Microbiol; 1987 Oct; 6(5):521-4. PubMed ID: 3481335
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
Wise R; Griggs D; Andrews JM
Rev Infect Dis; 1988; 10 Suppl 1():S83-9. PubMed ID: 3162327
[TBL] [Abstract][Full Text] [Related]
19. Furosemide disposition in cirrhotic patients.
Sawhney VK; Gregory PB; Swezey SE; Blaschke TF
Gastroenterology; 1981 Dec; 81(6):1012-6. PubMed ID: 7286579
[TBL] [Abstract][Full Text] [Related]
20. Penetration of pefloxacin and its desmethyl metabolite into the uroepithelium after a 800-mg single oral dose in human patients.
Moreau JL; Royer-Morrot MJ; Lozniewski A; Trackoen G; Delavault P; Royer RJ
Eur J Clin Pharmacol; 1996; 49(5):401-5. PubMed ID: 8866637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
